Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Skrabl-Baumgartner, A; Erwa, W; Muntean, W; Jahnel, J.
Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response.
Scand J Rheumatol. 2015; 44(5):359-362
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Erwa Wolfgang
Jahnel Jörg
Muntean Eugen
Skrabl-Baumgartner Andrea
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
We aimed to determine how loss of response (LOR) to adalimumab (ADA) in juvenile idiopathic arthritis (JIA) may be related to anti-ADA antibodies (AAA). AAA and ADA levels were measured in 23 consecutive patients with JIA responding significantly to treatment with ADA. Six out of 23 (26%) patients developed AAA and had low ADA levels. Five out of six AAA-positive patients experienced LOR. In these patients use of concomitant methotrexate (MTX) was significantly lower. The occurrence of AAA is a frequent event associated with LOR. Monitoring of AAA and serum ADA levels should be considered in JIA patients under ADA therapy.
Find related publications in this database (using NLM MeSH Indexing)
Adalimumab - blood
Adalimumab - immunology
Adalimumab - therapeutic use
Adolescent -
Antibodies, Anti-Idiotypic - blood
Antibodies, Anti-Idiotypic - immunology
Antirheumatic Agents - blood
Antirheumatic Agents - immunology
Antirheumatic Agents - therapeutic use
Arthritis, Juvenile - blood
Arthritis, Juvenile - drug therapy
Arthritis, Juvenile - immunology
Biomarkers - blood
Child -
Drug Therapy, Combination -
Female -
Humans -
Male -
Methotrexate - therapeutic use
Severity of Illness Index -
Treatment Failure -
Treatment Outcome -
Tumor Necrosis Factor-alpha - antagonists & inhibitors

© Meduni Graz Impressum